Testosterone pellets: legitimate concerns or overhyped TRT skepticism?

What did @dr.randmcclain actually say?

Dr. Rand McClain argued that testosterone pellets produce inconsistent hormone levels, describing a pattern of an early spike followed by a crash before the next insertion. He said patients can feel "almost manic with energy" in the first weeks, then have "none again" about a month before their next implant cycle. He stopped short of calling pellets useless, suggesting they work fine for people with modest goals, like fitting in "an extra round of golf" on weekends. That framing is worth examining closely, because the science is more complicated than his anecdote suggests.

His core claim is that pellet technology has not been developed to produce tight, stable testosterone release. He presents this as clinical observation rather than a reviewed finding, which is an important distinction when evaluating how seriously to take it.

Does the science back this up?

Partially, yes. The pharmacokinetic profile of subcutaneous testosterone pellets is genuinely less predictable than injections or gels in some patients, and the literature acknowledges this. But calling it uniformly erratic oversimplifies what the data actually shows.

A 2012 study by Bhattacharya et al. in The Journal of Sexual Medicine found that pellet-dosed patients achieved supraphysiologic testosterone levels in the early post-insertion period in a meaningful subset of cases. Similarly, a review by Pastuszak et al. (2017, Current Urology Reports) noted that pellet dosing remains less standardized than injectable or transdermal routes because pellet release rates depend on variables like insertion depth, vascularization, and physical activity level. Those factors do produce real inter-patient variability. However, the same review noted that many patients maintain levels within a therapeutic range for three to six months, which does not neatly fit the boom-and-bust narrative McClain describes. The crash he mentions one month before reimplantation is documented in some patients, but it is not universal.

What did they get wrong (or right)?

He got the general direction right but overstated the consistency of the problem. The spike-then-crash pattern he describes is real for some patients, and it is a legitimate reason to discuss delivery method carefully with a prescribing clinician. That is a fair clinical observation. What he got wrong, or at least oversimplified, is suggesting this is an inherent design flaw across all pellet formulations and all patients.

Pellet dosing can be titrated. Clinicians with experience in pellet therapy adjust the number and size of pellets based on body weight, activity level, and prior blood work. A 2019 retrospective study by Stanton et al. in Postgraduate Medicine found that women receiving testosterone pellets for low libido maintained levels in a stable therapeutic range over multiple insertion cycles when dosing was individualized. His framing that pellets are acceptable only for low-demand patients is an opinion, not a pharmacological conclusion. It also carries a dismissive tone that may discourage people from exploring a delivery method that works well for others.

What should you actually know?

If you are considering testosterone pellets, the honest answer is that your experience will depend heavily on who is inserting them and how they are calculating your dose. The variability McClain describes is real but not inevitable. Blood work every six to eight weeks after insertion, at least during early cycles, is the standard way to catch a dosing problem before it becomes a clinical issue.

• Pellet release is influenced by physical activity. High-intensity training accelerates absorption, which can shorten the effective window and contribute to the crash pattern McClain describes.
• Injectable testosterone, typically cypionate or enanthate, gives clinicians more precise control over peaks and troughs and allows dose adjustment without a minor procedure.
• No delivery method is universally superior. The right choice depends on lifestyle, adherence, tolerance for injections, and how closely you will be monitored.
• The FDA has not approved any subcutaneous testosterone pellet product for general use. Pellets are compounded preparations, which means manufacturing standards vary by pharmacy. That is a separate and legitimate concern about quality consistency that McClain does not raise.

The bottom line

McClain raises a real issue in a way that is partially supported by pharmacokinetic literature. Pellet variability is documented, especially in patients with high activity levels or suboptimal dosing. But the claim that pellets are only suitable for low-effort lifestyle goals is an opinion dressed up as a clinical finding. If you are on TRT or considering it, the delivery method conversation should happen with a clinician who reviews your labs, not a TikTok video with 1,400 views. Demand bloodwork, not just a vibe-based pellet insertion.